~~<i id='02681504BE'><strike id='02681504BE'><tt id='02681504BE'><pre id='02681504BE'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

knowledge

author：explore 2025-09-14 21:44:39 - browse：9

JOHNSON & JOHNSON HEADQUARTERS — Daniel Hulshizer/AP

Eight months into his tenure, Johnson & Johnson’s R&D chief is putting a big emphasis on medicines for cancer, treatment-resistant depression, and autoimmune disease.

To sharpen that focus, R&D chief John Reed told STAT that the company is de-emphasizing two areas that have been mainstays for the drug and medical device giant: infectious disease and vaccines, as well as medicines targeting kidney disease and rare eye conditions.

The disclosures were made in an interview ahead of an investor meeting Reed is leading Tuesday aimed at generating excitement about the company’s research and development efforts.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

entertainment

hotspot

focus

hotspot

focus

NationalInstitutesofHealthDirectorMonicaBertagnollitestifiesduringherSenateHELPCommitteeconfirmation

WSS

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

Carbon Health diabetes program, a test of data

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Publishing genetic code of viruses could cause disaster

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Oprah kicked off a national conversation on obesity. Let's have it

leisure time

knowledge

entertainment

State Dept. review finds Biden bears some blame for Afghanistan failures

FDA's naming rule on biosimilars has undermined competition

In age of alternative facts, a scholarly course on calling out crap

Readout Newsletter: Merck, Vertex, and Viking updates

Bright Health sells Medicare Advantage business to Molina

A letter from the executive editor: STAT UnitedHealth investigation

Activists slam private health insurers over coverage restrictions

Ventyx halts psoriasis drug development after lackluster trial results

Peter Hotez and the public health issue of online harassment

Publishing genetic code of viruses could cause disaster

hotspot

CVS, Rite Aid closures threaten to worsen pharmacy deserts

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

Why the world’s most expensive drug might be worth the price

FDA reorg will put new emphasis on investigations, sources say

After decades in use, heart stents finally beat placebo

focus

hotspot

hotspot

focus